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Abstract An important goal of toxicology is to under-
stand and predict the adverse effects of drugs and other
xenobiotics. For pharmaceuticals, such effects often emerge
unexpectedly in man even when absent from trials in vitro
and in animals. Although drugs and xenobiotics act on
molecules, it is their perturbation of intracellular networks
that matters. The tremendous complexity of these networks
makes it difficult to understand the effects of xenobiotics on
their ability to function. Because systems biology integrates
data concerning molecules and their interactions into an
understanding of network behaviour, it should be able to
assist toxicology in this respect. This review identifies how
in silico systems biology tools, such as kinetic modelling,
and metabolic control, robustness and flux analyse, may
indeed help understanding network-mediated toxicity. It
also shows how these approaches function by implementing
them vis-a`-vis the glutathione network, which is important
for the detoxification of reactive drug metabolites. The tools
enable the appreciation of the steady state concept for the
detoxification network and make it possible to simulate and
then understand effects of perturbations of the macromol-
ecules in the pathway that are counterintuitive. We review
how a glutathione model has been used to explain the
impact of perturbation of the pathway at various molecular
sites, as would be the effect of single-nucleotide polymor-
phisms. We focus on how the mutations impact the levels of
glutathione and of two candidate biomarkers of hepatic
glutathione status. We conclude this review by sketching
how the various systems biology tools may help in the
various phases of drug development in the pharmaceutical
industry.
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Introduction
In recent years, system-level understanding has been a
recurrent theme in biological science and has greatly
improved our understanding of the function and regulation
of many different processes. In particular, the new disci-
pline systems biology has provided a framework for
investigating the interactions between the separate parts of
biological systems in order to understand its functioning.
One field where this approach has the potential to add
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significant value is toxicology. In particular, it is now
recognised that many commonly prescribed drugs cause
rare and unexpected adverse effects in man. These drug-
induced adverse reactions are a leading cause of human ill
health, restricted drug usage, failed licensing and with-
drawal of licensed drugs from clinical use. Therefore, they
are of major clinical and socioeconomic importance.
The mechanisms that underlie adverse drug reactions are
complex and involve multiple biological processes. The
latter may include cellular uptake and efflux mediated by
specific membrane transport proteins, metabolic biotrans-
formation (often to chemically reactive metabolites), off-
target interactions of the drug and/or its metabolites with
tissue macromolecules, downstream interactions between
cells and activation of innate and/or adaptive immune
responses. Our understanding of the inter-relationships
between these events is incomplete. In particular, it is
unclear which of the different processes can explain why
relatively few patients are susceptible to adverse drug
reactions whereas the vast majority of drug-treated patients
are not. As an essential first step, a rigorous understanding
is required of the intracellular networks affected by drugs,
their metabolites and their molecular targets, and of how
these can act in concert with either causing toxicity or
preventing toxicity from arising.
It is a frequent mistake to assume that systems biology
is focussed on system-level or holistic understanding
(Alberghina and Westerhoff 2005). It is not: physiology is
the science of the whole; molecular biology is the science of
the parts; systems biology is the scientific discipline that
encompasses and describes relationships between the two.
Systems biology therefore involves assessment of biologi-
cal function at the level of network interactions. The rele-
vant networks start at the molecular level, are genome-wide
and ultimately relate to the functioning of the organism
as a whole. An important feature of systems biology is that
it focuses upon the emergent properties of the system.
Emergent properties are functional properties not present
within the individual components of the system, which only
arise when system components interact. An example is the
interaction between hydrogen and oxygen to make water.
The resulting change in properties is unpredictable if only
the individual properties of hydrogen and oxygen are
known (Aderem 2005). Systems biology is confined to
cases where the emergent properties are important for bio-
logical function, that is, for the maintenance of the living
state, for dysfunction such as in disease and for malfunc-
tions such as in the case of toxicity. In the context of this
review, systems biology addresses much of the toxicity of
adverse drug reactions (ADRs).
Once the system can be understood to the point that
emergent properties can be explained, then biology can
start to move from being a descriptive science to being a
more predictive science (Materi and Wishart 2007). Once
biology is a more predictive science, it should become
possible to predict off-target effects of drugs as well as
network effects of affected targets. Even a minor advance
in predictive capabilities may help both the research into
new drugs and their toxicity, and decisions concerning
whether or not to advance new drug candidates towards the
market (Westerhoff et al. 2008).
Glutathione metabolism is important for toxicology as it
is vital in binding and neutralising reactive species pro-
duced in, for example, the liver via the metabolism of
xenobiotics by the formation of glutathione conjugates
(Ketterer et al. 1983). When the dose of reactive metabo-
lites exceeds the capacity of this defence system to
replenish glutathione through new synthesis, glutathione
depletion occurs. For a variety of toxic compounds, it has
been found that the depletion of glutathione precedes the
covalent binding of chemically reactive metabolites to
cellular macromolecules, oxidative stress and, ultimately,
organelle injury with the potential for liver failure and
death (Park et al. 2011). A more complete understanding of
the events that lead to hepatic glutathione depletion might
therefore highlight new and sensitive biomarkers and pro-
vide insights into key steps in glutathione production,
thereby leading to improvements in risk assessment for
new, and existing, drugs and xenobiotics.
In this review, we shall provide an outline of the
available in silico systems biology tools that might be of
use to toxicology. We will discuss to what extent these
tools have been applied already and how they can be
beneficial in toxicology. In addition, these tools are
exemplified by being applied to a model of glutathione
metabolism, where possible, to illustrate their utility.
Creating a model
Biological systems are highly complex due to both the
number of components present and the nonlinear interac-
tions between them (Kitano 2002). In order to understand
emergent properties of the system, the interactions between
the components must be studied. Components such as
enzymes only ‘talk’ to the rest of the system through the
rates at which they consume or produce small molecules.
The reaction rates are governed by kinetics such as
Michaelis–Menten and Hill equations, which express the
dependence of the reaction rates on the concentrations of
the small molecules in the systems; this is how the enzymes
‘listen’ to each other through the altering concentrations of
the small molecules. Only rarely, the integration of the
concentration of the small molecules over a period of time
can be understood without computer help. An important
part of systems biology is therefore collecting the
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experimental data of components of a system into a math-
ematical model (Alberghina and Westerhoff 2005) and
integrating that model over time. Such models of biological
systems have many uses (Hornberg et al. 2007), some of
which are mentioned here. Firstly, comparisons between
experimental observation and the mathematical model
behaviour can link knowledge of system components to
explanations of system behaviour. These new explanations
might have been elusive in the past due to the focus on
single molecules. Secondly, in silico experiments can be
carried out on the model to test the effects of perturbations
on the system and to identify the processes that control the
system. These experiments may either be only feasible
using a computer, or are faster and cheaper than laboratory
experiments (Bakker et al. 2000). Such ‘dry’ experiments
may generate new hypotheses about the system, which can
then be tested experimentally. Simulation can also be used
as a tool for experimental design. In an iterative process, the
results of further experiments can then be used to improve
the model until such a time as the model is sufficiently good
as to be considered equivalent to its biological test systems
in terms of ability to predict outcomes of experiments. At
this point, the biological experiments become redundant.
There are several examples of modelling applied in
toxicology (Krishnan and Andersen 2010). One popular
type is physiologically based pharmacokinetic (PBPK)
models. These models investigate variables such as the rates
of absorption, distribution, excretion, and biotransformation
of chemicals and their metabolites. In toxicology research
and chemical risk assessment, they are used to make more
accurate predictions of target tissue dose for different
exposure situations (Andersen 1995). Other models simu-
late electrophysiological activity to assess the potential
cardiotoxicity of cardiac drugs (Rodriguez et al. 2010),
identify the important parameters in hepatocyte regenera-
tion following toxicity using single cell–based spatial–
temporal models (Ho¨hme et al. 2007) or show the feasibility
of examining toxicology pathways in kinetic detail (Reed
et al. 2008).
For toxicology, using models in terms of rate equations
and balance equations, together culminating in ordinary
differential equations (ODEs), would be beneficial as it is a
well-understood formalism, fast and mathematically robust.
It also lends itself to thorough interpretation via metabolic
control analysis (MCA), elementary mode analysis (EMA)
and flux balance analysis (FBA), which are tools that can
help understand how a system functions (vide infra).
In the ODE methodology, the biochemistry of the reac-
tions is essentially translated into mathematics. The bio-
logical system and the corresponding network of chemical
reactions are described in terms of a set of balance equations
with reaction stoichiometries indicating which metabolite is
produced or consumed in which reaction, plus a set of
reaction rate equations. The ODEs resulting from the
combination of these two sets are then solved using
numerical methods. Most processes in biological systems
are catalysed by enzymes or transporters. Examples of well-
known and popular equations used to describe enzyme
catalysed reactions are mass action and Michaelis–Menten
kinetics (Cornish-Bowden 1995). For more information on
enzyme kinetics and the equations used for this kind of
modelling, please refer to ‘Appendix’.
In the past, modelling has been unattractive to experi-
mental biologists due to the necessity to acquire extensive
programming and mathematic knowledge. This should no
longer be the case. A number of software packages have
been put together to perform several mathematical tasks and
to make modelling more user-friendly. Different software
packages have been designed for users of different back-
grounds as reviewed in some detail by Alves et al. (2006).
Modelling simulators such as COPASI provide access to
powerful systems biology tools while remaining accessible
to non-expert modellers (Hoops et al. 2006). Examples of
kinetic models are available in model repositories such as
JWS online [http://www.jjj.bio.vu.nl/; (Olivier and Snoep
2004; Materi and Wishart 2007)] that enable in silico
experimentation with the existing models without exposing
the user to the detailed mathematics [cf. Biomodels (http://
www.ebi.ac.uk/biomodels-main/)]. Models include those of
glycolysis in human erythrocytes (Mulquiney and Kuchel
1999), glycolysis in Trypanosoma brucei (Helfert et al.
2001) and the methionine/threonine metabolism in Arabid-
opsis (Curien et al. 2009).
Below, a model of glutathione metabolism by Geenen
et al. (in press; cf Fig. 1) will be investigated as an example.
The model can be found under (http://jjj.mib.ac.uk/
webMathematica/Examples/run.jsp?modelName=geenen).
It was based on kinetic equations taken from a previously
published model (Reed et al. 2008) and expanded by adding
equations for the gamma-glutamyl cycle, ophthalmic acid
synthesis and detoxification of paracetamol (acetamino-
phen). Some of the parameter values used for the creation of
the model are uncertain, and the lack of data required for
validation means that we are not confident at the ability of
the model to make quantitatively correct predictions. Here,
we use this model to illustrate systems biology tools and to
create testable hypotheses for further analyses. The more
specific conclusions of the model are of limited certainty.
The network of biochemical reactions modelled is pre-
sented in Fig. 1. Starting from methionine at the top, a long
pathway leads to reduced glutathione, which can then be
conjugated to a xenobiotic such as paracetamol. This then
leads to the removal of the xenobiotic as the glutathione
conjugate. Glutathione can also be made from 5-oxopro-
line, which can in turn be synthesised from glutathione
through a partly extracellular route. The precursor of
Arch Toxicol (2012) 86:1251–1271 1253
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glutathione can release a cysteine to return to 5-oxoproline.
The overall scheme is complex, and the presence of at least
three reaction cycles makes it difficult to predict how
changes in the activity in any of the enzymes (or the gene
that encode them) will affect the level of glutathione, the
rate of detoxification, or the concentrations of metabolites
and potential biomarkers such as 5-oxoproline.
Systems biology computational methods
A mathematical representation of biology is not the aim of
systems biology. Rather, computational models are viewed
as tools to help the human mind in understanding the
behaviour of the networks of biology. The insight gained
by modelling is more extensive than what is possible by
experimentation alone. This is because the networks of
biology are too complex for their behaviour to be predicted
by the unaided human brain. In biology simplicity is rare,
because living systems are essentially complex (Westerhoff
et al. 2009). These models therefore can also get complex,
and thus we need modelling tools to be able to understand
these networks and particularly the role that specific mol-
ecules such as drugs, drug targets and drug metabolisers
play in them.
Because detailed experimental analysis of the networks
in humans is virtually impossible, and tissue culture cells
and animal models are rarely reliably representative of the
in vivo situation in humans, it might hereby seem that
mathematical models are the methods of choice. This is not
yet so, however. The catch is that for the models to be
made, much experimental information is required; none of
the models of the type required here can be made ab initio.
It is a property of the highly nonlinear networks of life such
Fig. 1 The reaction network in
the mathematical model of
glutathione metabolism made
by Geenen et al. (in press) for
liver. The network embraces
methionine catabolism,
glutathione metabolism,
5-oxoproline and ophthalmic
acid synthesis and glutathione-
mediated detoxification
pathways. Metabolites are
indicated by ovals; enzymes and
rates are shown in italics
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that their behaviour depends strongly on the values of
many parameters that are products of the evolution of the
macromolecules. These parameter values can almost only
be determined experimentally. To date there is no single
network in biology for which a completely validated
dynamic model has been made, although some pathways
are perhaps getting close. A slightly but not yet very suc-
cessful (Westerhoff et al. 2010) alternative method is found
in flux balance analysis with objective functions: If one
knows which functions the network has been optimised for
in evolution, then one may arrive at complete descriptions
of systems fluxes.
Steady state analysis
Once the concentrations of the chemical substances in the
system have integrated so as to give zero further change in
concentrations over time, a steady state is reached. The
concentrations and fluxes of the model at this steady state
often represent the functions of the biological system that is
being modelled. Steady states therefore can contain a lot of
information. The steady state of a model can be readily
calculated in software such as COPASI, or even more
directly, that is at the click of a button in JWSonline (http://
jjj.mib.ac.uk/) (Olivier and Snoep 2004).
For the diagram of Fig. 1, Geenen et al. (in press) have
collected the best present estimates of the parameter values,
as well as the best known rate equations, and have assembled
these into a rate plus balance equations model, which can
now be integrated by JWSonline. The column entitled
‘Normal’ in Table 1 gives the steady state concentrations
and flux values for the reactions, as predicted by the model.
It is clear that without the model, it would have been difficult
to predict these flux values, which correspond to what is
implied by the best of our understanding of the glutathione
pathway. On the other hand, this understanding is incom-
plete, and we should not put too much trust in the precise
values of the fluxes andmetabolites at this stage. If not for the
precise values, what else can one use the model for?
We will first use the model to verify our understanding
of the fundamentals of the modelling strategies and of
certain principles of networks functioning at steady state.
The flux values in Table 1 enable us to appreciate that at
each ‘node’ (a node is any metabolite in the network for
which the concentration may vary with time until the
steady state is achieved), the total carbon flux into the node
equals the total carbon flux out of it. For instance, at the
node cglc (c-glutamyl-cysteine) in Fig. 2, the flux syn-
thesising glutamyl-cysteine is 940 lM/h (v10) and the flux
degrading glutamyl-cysteine is 830 lM/h through reac-
tion 24 and 110 lM/h through reaction 11. This results in a
net rate of change of zero and thus no change in the con-
centration of glutamyl-cysteine with time.
Table 1 Changes in the steady state of the Geenen et al. (in press)
standard model under normal conditions, when VGSf1 is reduced from
948 to 200 or when VOP is reduced from 846,930 to 10,000
Variable Normal Reduced VGS Reduced VOP
ASG 0.0043 0.0053 0.0046
bcys 180 181 180
bgluAA 1.1 0.75 1.1
bGSH 8.1 5.7 8.6
bGSSG 0.49 0.27 0.52
cCH2THF 0.33 0.31 0.34
ccys 210 304 190
cglc 190 640 220
cgluAA 4.7 4.8 5.2
cglut 540 1,200 470
cgly 1,800 2,200 1,700
cGSH 1,500 1,000 1,600
cGSSG 69 38 74
cTHF 5.3 5.7 5.2
cysASG 5 5 5
cysgly 3.6 3.1 3.7
cyt 33 34 33
gluAB 2.7 32 1.4
glyASG 92 110 88
hcy 1.1 1.1 1.1
met 48 47 48
OPA 1 1 1
oxo 2.5 5.8 3.1
SAH 19 20 19
SAM 38 37 38
v[1] 120 120 120
v[2] 66 66 66
v[3] 130 130 130
v[4] 57 59 57
v[5] 190 190 190
v[6] 61 62 61
v[7] 38 37 38
v[8] 90 90 89
v[9] 90 90 89
v[10] 940 1,000 27
v[11] 110 79 120
v[12] 55 36 58
v[13] 50 33 52
v[14] 3.9 2.1 4.1
v[15] 1.1 0.63 1.2
v[16] 42 13 47
v[17] 62 60 63
v[18] 12 11 12
v[19] 25 -12 31
v[20] 150 120 150
v[21] 24 23 25
v[22] 38 37 38
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Another semi-quantitative issue that the modelling can
address is what the major fluxes are in the pathway. Is the
flux from methionine to glutathione indeed the dominant
flux? The answer is perhaps surprising: no. According to
Table 1, the production of c-glutamyl-cysteine (cglc) from
cysteine and glutamate in reaction 10 at a rate of 940 lM/
h, the production of glutamate from 5-oxoproline at a rate
of 930 lM/h (reaction v25) and the production of 5-oxo-
proline from c-glutamyl-cysteine (v24) at a rate of 830 lM/
h are ten times higher than the flux through reaction 8. This
makes for a large cyclic flux around reactions v24, v25 and
v10 of 830 lM/h to be dominant. This may be unexpected
considering that this is a so-called ‘futile cycle’, which
hydrolyses ATP. This suggests that either a strong ability to
regulate, which could be an effect of the futile cycle, is to
be discovered here, or our molecular understanding of the
pathway is still incomplete. Perhaps not all enzymes of the
cycle are expressed simultaneously.
Interindividual variation in glutathione metabolism
The same model can help understand the disease 5-oxo-
prolinuria. 5-Oxoprolinuria is an inherited disorder of glu-
tathione metabolism, which causes a decrease in glutathione
concentration and an increase in 5-oxoproline concentration
(a glutathione metabolism by-product) in the urine. The
literature is unclear as to the mechanism of 5-oxoprolinuria.
Some researchers have suggested that this occurs via a
deficiency in glutathione synthetase (GS). They presumed
that this deficiency causes a low glutathione concentration,
which they expected to overstimulate c–glutamyl-cysteine
synthesis, and thus 5-oxoproline formation (Shi et al. 1996).
Another possible cause of 5-oxoprolinuria is a disruption in
the 5-oxoprolinase enzyme (which catalyses reaction 25 in
Fig. 1), which is hypothesised to directly increase the
5-oxoproline concentration in the cell (Croal et al. 1998).
We would hypothesise that in practice there is a plethora of
causes of 5-oxoprolinuria, that is, any single-nucleotide
polymorphism affecting an enzyme activity with control
over the level of 5-oxoproline without causing embryonic
lethality. But that is not the issue here.
Here, we examine the realism of the former two expli-
cations. If one decreases the Vmax of GS in our model by a
factor of 4.7, the concentration of reduced glutathione
decreases, but by a mere third, while the concentration and
the export rate of 5-oxoproline (v38) increase by factors of
2 and 3, respectively. Using the scan function of JWSon-
line, it is possible to analyse more precisely how the model
predicts the export rate v38 to vary with the Vmax of GS
(VGSf1). Fig. 3 shows that a reduction in the glutathione
synthetase (GS) activity is predicted to increase the efflux
for 5-oxoproline from the cells, confirming deficiencies in
GS as possible basis for the disease.
The other proposed explanation for 5-oxoprolinuria may
also be examined by an in silico experiment, decreasing the
5-oxoprolinase activity (VOP; reaction 25 in Fig. 1). In this
case, no significant increase in 5-oxoproline export (v38) was
observed (Fig. 4). From this, we hypothesise that the more
effective cause of 5-oxoprolinuria is a decrease in the gluta-
thione synthetase, not a decrease in the 5-oxoprolinase activity.
Fig. 2 The conservation of the glutamyl-cysteine concentration at
steady state. Reactions v10, v11 and v24 were taken from Fig. 1. The
steady state reaction rates in the model are given in italics (from
Table 1)
Table 1 continued
Variable Normal Reduced VGS Reduced VOP
v[23] 14 14 14
v[24] 830 930 -94
v[25] 930 1,000 15
v[26] 1.5 3.9 0.67
v[27] 1.5 3.9 0.67
v[28] 100 73 110
v[29] 100 73 110
v[30] 100 73 110
v[31] 100 73 110
v[32] 1.5 3.9 0.67
v[33] 0 0 0
v[34] 0 0 0
v[35] 0 0 0
v[36] 0 0 0
v[37] 0 0 0
v[38] 0.57 1.8 0.79
v[39] 90 90 89
v[40] 5 2.8 5.3
v[41] 90 90 89
Simulations used JWSonline (results reported in terms of the two
most significant digits). Metabolite concentrations are in lM, and
fluxes are in lM/h. Paracetamol was considered to be absent. Fluxes
can be related to reactions using Fig. 1. bX refers to the concentration
of X in the serum. cX refers to the concentration of X in the cytosol.
‘Normal’: standard parameter values including VGS = 948 and
VOP = 846,930. ‘Reduced VGS’: standard parameter values except for
VGS = 200. ‘Reduced VOP’: standard parameter values except for
VOP = 10,000
1256 Arch Toxicol (2012) 86:1251–1271
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These findings are partly counterintuitive. A decrease in
the activity of GS (reaction 11) might be expected to
decrease the level of extracellular glutathione and thereby
the synthesis of 5-oxoproline through reactions 28, 30 and
31, with a concomitant decrease in the intracellular level
and efflux of 5-oxoproline, contrary to the modelling
results. Again, inspecting Fig. 1, one might expect a
decrease in the Vmax of reaction 25 to lead to an increase in
the 5-oxoproline concentration and an increase in 5-oxo-
proline efflux (reaction 38), again deviating from the
results of the modelling. By looking at the steady state
values in Table 1, one can examine why these intuitive
predictions would be incorrect (illustrated in Fig. 5). When
GS activity is reduced, this should first reduce the rate of
reaction 11, thereby causing the concentration of c–glut-
amyl-cysteine (cglc in Table 1) to increase and the con-
centration of glutathione (cGSH) to decrease as confirmed
by the model calculations (v11 changes from 110 lM/h to
79 lM/h, cglc changes from 0.19 to 0.64 mM and GSH
changes from 1.5 to 1.0 mM; cf. the third column in
Table 1). The rather substantial increase in c–glutamyl-
cysteine might be expected to decrease the flux through
v10. Paradoxically, this flux is increased, however, by some
7 % from 940 to 1,000 lM/h. Consequently, the cause of
the increase in 5-oxoproline cannot involve product inhi-
bition of reactions 10 and 25. Rather, it must be due to the
increase in the concentration of c–glutamyl pushing more
flux through reaction 24 (from 830 to 930 lM/h) increas-
ing the rate of production of 5-oxoproline. Apparently, this
increase is enough to compensate for the decrease in v31
due to the decrease in v11 and the increase in 5-oxoproline,
and consequent increase in glutamate (cf. Table 1) now
leads to the paradoxical increase in reaction 10, as men-
tioned above. This pushes the intracellular 5-oxoproline up,
with a consequent increase in 5-oxoproline export. The
above finding shows that indeed the proper cause–effect
relationship in a network as complex as glutathione
metabolism cannot be reliably identified by mere inspec-
tion of network topology. Modelling is required for fol-
lowing the logics of biology.
This is illustrated further when VOP (reaction 25) is
reduced by a factor of 8.5 (final column in Table 1): this
brings about an increase in the 5-oxoproline concentration
by only 25 % (from 2.5 to 3.1 lM) so that reaction v24
changes direction and degrades 5-oxoproline back into the
glutathione cycle instead of much more of the substance
being exported from the cell: the export reaction increases
by a mere 20 % (from 0.57 to 0.79). We emphasise that we
are here discussing the performance of what may be the
best possible mathematical model of the pathway and that
these conclusions are subject to experimental validation.
The calculations show, however, how the model can serve
as a vehicle for explanation and a method for the sugges-
tion of key experimental measurements.
Fig. 3 The variation of 5-oxoproline export (V38) with the Vmax of
glutathione synthetase (VGSf1), as predicted by the model. Calculated
using the scan function of JWSonline (scanning VGSf1 from 1 to
1,000)
Fig. 4 5-Oxoproline export (V38) predicted for the variation of the
Vmax of 5-oxoprolinase (VOP). The scan function of JWSonline
(scanning VOP from 1 to 10,000) was used
Fig. 5 Changes in fluxes around glutathione induced by reactions
v10, v11, v24, v31, v38 and v25 taken from Fig. 1 in order to show the
hypothesised mechanism of 5-oxoprolinuria. The changes in steady
state flux for the shift in condition between normal (VGSf1 = 948) and
reduced GS (VGSf1 = 200) are shown in the figure. Flux is in lM/h
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Metabolic control analysis
In order to understand emergent properties of the system,
the interactions between the components must be studied.
But studying the emergent properties does not always
require the full dynamics of the network. If one is inter-
ested exclusively in the control of fluxes and concentra-
tions in the network, then there is a simpler way to
determine and quantify the control of emergent properties
and to calculate how control emerges from the interactive
properties of the components of the network: metabolic
control analysis (MCA). In principle, this approach could
help to determine the processes in the network that deter-
mine the toxicity of a given drug.
Although it is still the prevailing view that the flux
through a pathway is necessarily set by one rate-limiting
enzyme; this view has been shown to be false (Groen et al.
1982a). MCA enables one to deal with the possibility that
the control of flux through the pathway is shared. The flux
control coefficient (CJ
i
) for example is defined as the per-
centage change in a specified steady state metabolic flux (J)
that is caused by a one per cent change in activity (v) of any
enzyme alone, or more precisely:
CJvi ¼
o ln J
op
 
system steady state
o ln vi
op
 
all metabolite concentrations constant
In words, one here adds an inhibitor p specific for an
enzyme i. One measures the relative (‘fold-change’) effect
on the flux of the pathway in the intact system (i.e. dlnJ).
One then compares this (by division) to the effect the
inhibitor would have on the flux through the enzyme if
the enzyme were studied in isolation dlnvi. After all, in the
pathway, homeostatic responses will reduce the effect on
the flux. If the inhibitor were to reduce the pathway flux by
only 20 % at a concentration where it would inhibit the
enzyme in isolation for 50 %, the control coefficient would
be only 20/50 = 0.4.
Here, the activities of all other enzymes are kept con-
stant (Kholodenko et al. 1995), and p is a parameter that
only affects enzyme i. When the control coefficient is 1,
then the change in flux is proportional to the change in the
activity of the reaction. When its flux control coefficient is
0, the enzyme is not limiting the flux at all. These two
options already existed in the classical view of the control
of metabolism, that is, an enzyme was either the rate-
limiting step (C = 1) or not rate-limiting at all (C = 0).
The above definition enables one to deal with the inter-
mediate case where an enzyme carries partial flux control,
that is, somewhat but not completely rate-limiting. In such
cases, the flux control might be 0.3 or 0.7. This has allowed
the establishment of the pattern of flux control for a number
of cases both directly and experimentally (Bakker et al.
1999; Groen et al. 1982a) and by an integration of exper-
imental data into a model (Bakker et al. 1999; Groen et al.
1982a).
As an increase in all enzyme activities by 1 % leads to a
1 % increase in flux through a pathway, it can be shown
that the sum of the flux control coefficients is 1 (Hornberg
et al. 2007). This is called the summation law (Kacser and
Burns 1973; Heinrich and Rapoport 1974):
Xn
i¼1
CJi ¼ C
J
1 þ C
J
2 . . . þ C
J
n ¼ 1
The same principle can be applied to concentration control
analysis, where the effect of a change in metabolite con-
centration on the flux is measured. Then, the analogy of the
above sum amounts to zero.
A related parameter is the elasticity coefficient. This is a
local parameter of an enzyme that shows how perturbations
of a reaction parameter affect the local reaction rate.
‘Local’ means that the effect is to be measured without
taking into account the changes in the environment of the
enzyme that may be caused by its reduced activity. The
elasticity coefficient does not take network effects into
account, whereas the control coefficients do. Indeed, the
perspective of elasticity differs from that around the control
coefficients, as the elasticity is not directly a systemic
property, although its magnitude does depend on properties
of the system.
The elasticity coefficients are defined as the ratio of
relative change in local rate to the relative change in one
parameter (normally the concentration of an effector).
eip ¼
ovi
op

p
vi
¼
o ln vi
o ln p
 
all other metabolite concentrations constant
where vi is the rate of the enzyme and p is the parameter we
are perturbing. This means one could measure the relative
(‘fold-change’) effect on the rate of a reaction in response
to/compared with (by division) a relative (‘fold-change’) in
the parameter of interest. Each enzyme has as many elas-
ticity coefficients as the number of parameters that affect it
directly, for example, reaction substrates, products and
effectors.
A particularly useful and important feature of MCA is
that it can relate the kinetic properties of the individual
reactions (local properties) to (global) properties of the
whole intact pathway. MCA therefore shows how local
properties within the system give rise to system-level
properties, that is, MCA shows the emergence. This is done
through the connectivity theorems that relate the control
coefficients to the elasticity coefficients.
The connectivity theorem for flux control coefficients
(Kacser and Burns 1973) states that, for a common
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metabolite S, the sum of the products of the flux control
coefficient of all (i) steps affected by S and its elasticity
coefficients towards S is zero:X
i
CJi e
i
½S ¼ 0
For the concentration control coefficients, two equations
can apply, depending on whether or not the metabolite, the
concentration of which is being controlled, is the same as
the metabolite for which the elasticity coefficients are
considered (Westerhoff and Kell 1984):
P
i
C
½S
i e
i
½S ¼ ÿ1P
i
C
½A
i e
i
½S ¼ 0 for S 6¼ A
Control coefficients can also be applied in drug efficacy
measurements by measuring the effect of an inhibitor of an
enzyme on the flux through the system. A corresponding
response coefficient is defined as the percentage change in
a specified steady state metabolic flux that is caused by a
one per cent change in concentration of a drug or by an
amount of drug that causes 1 % inactivation of the enzyme
when in isolation (Groen et al. 1982b; Chen and
Westerhoff 1986; Bakker et al. 2002).
An example of how modelling of a system can lead to
the discovery of new drug targets can be found in the
metabolic control analysis in the glycolytic pathway of
the parasite T. brucei. This parasite is responsible for the
African sleeping sickness and lives part of its population
life cycle in the mammalian blood stream. The strongest
flux control resided in the glucose transport step. This led
to the prediction that the glucose transporter is the best
predicted drug target, rather than glyceraldehyde-3-phos-
phate dehydrogenase, which is the drug target that is
mostly worked on (Bakker et al. 1999). The next step is
here to perform differential control analysis, which com-
pares the flux through a single metabolic pathway in a
pathogen and host, finding the control coefficients in both.
The steps with the largest difference in control coefficient
(higher control in pathogen than in host) can be identified
as having the greatest potential for specifically inhibiting
flux through the pathogen metabolic pathway. Bakker et al.
(2002) integrated this new approach with molecule-based
drug design. T. brucei is also a model system for tumour
cells in the mammalian host, where the tumour cells need
to be killed by drugs that should not be toxic for the host
cells. Again, one should develop drugs that impinge on
steps with high flux control in the tumour cell and small
flux control on, hence low toxicity for, normal host cells.
Differential control analysis has also been performed for
oncogenic signalling to gain information on potential drug
sites (Hornberg et al. 2007).
By analysing which reactions have control or high fra-
gility in a detoxification pathway, it is possible to predict
which steps in a pathway are sensitive to drug-induced
changes. Additionally, by analysing how control might
change in situations such as malnutrition and genetic
defects, it may be possible to predict an individual’s sen-
sitivity to toxicity from a certain drug.
MCA has been applied to the glutathione model to
demonstrate the control of methionine influx on the ability
of the cell to protect itself from paracetamol toxicity
(Geenen et al. in press). We can also use MCA to explain
the findings we have made in this paper regarding 5-oxo-
prolinuria. The control coefficients of the model were
analysed by using the metabolic control analysis task in
COPASI. This model is available in SBML format from the
authors and from JWSonline, which can be loaded into
COPASI for analysis. Table 2 shows the flux control
coefficients of GCS, GS and OP on 5-oxoproline export
(i.e. the effect that a change in the individual Vmax’s of
GCS, GS or OP would have on the export rate of 5-oxo-
proline) under three conditions. Under normal and gluta-
thione synthetase–limiting conditions the control is
strongest in the glutathione synthetase (control of -0.71
and -0.79) showing this is the more limiting step. The
negative value of these control coefficients reflects that an
increase in the activity of the enzyme leads to a decrease in
the flux, as expected. When VOP is decreased, the control in
5-oxoprolinase is also decreased, again supporting the
expectation that decreased 5-oxoprolinase does not lead to
much of an increase in 5-oxoproline.
Hierarchical regulation analysis (RA)
Control analysis examines which steps control or limit a
flux or a concentration. This gives an answer to the ‘what-if
question’: ‘what is the percentage effect on the flux if an
enzyme is activated by 1 %?’. If a certain enzyme has a
flux control coefficient of, say, 0.7, then this does not
guarantee that the system itself actually activates this
enzyme by 1 % when it needs to increase the flux through
Table 2 The control exercised by GCS, GS and OP on 5-oxoproline
export flux under three conditions: normal steady state, reduced
glutathione synthetase activity (VGsf1 = 200 rather than 948) and
reduced 5-oxoprolinase activity (VOP = 10,000 rather than 846,930).
Flux control is quantified in terms of the flux control coefficient
(Groen et al. 1982a)
Control by ; Parameter values
Normal VGS = 200 VOP = 10,000
Glutamylcysteine synthetase 0.25 0.16 0.008
Glutathione synthetase -0.71 -0.79 -0.55
5-Oxoprolinase -0.27 -0.16 -0.0052
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the system by 0.7 %. The organism that is host to the
pathway may or may not activate the enzyme when it
responds to an external challenge, such as a drug. It has
been the development of regulation analysis that has
brought this crucial distinction between control (=limita-
tion) and actual regulation to the fore. Hierarchical regu-
lation analysis (ter Kuile and Westerhoff 2001) is a
quantitative method for investigating whether the regula-
tion of flux through a system is metabolic or depends on
alterations in gene expression.
When an organism needs to increase the steady state flux
through a pathway, it needs to increase the fluxes through
all the enzymes in that pathway. For each enzyme, the
organism is able to increase the flux by regulating it
through gene expression, through signal transduction
(leading to covalent modification and activation of the
enzyme), or metabolically (i.e. by increasing the concen-
tration of its substrate or allosteric modifiers or by
decreasing the concentration of its product). The former
two types of regulation have been quantified together by
the so-called hierarchical regulation coefficient (qh), con-
sisting of a gene expression regulation coefficient and a
signal-transduction regulation coefficient. The metabolic
regulation has been quantified by the metabolic regulation
coefficient (qm). At steady state, the sum of qh and qm
equals one. This means that 100 % of regulation is dis-
tributed between gene expression, signal transduction and
metabolic regulation (ter Kuile and Westerhoff 2001;
Westerhoff et al. 2009).
Historically, the flow of information from DNA to RNA
to protein to function has suggested to some that regulation
is exclusively hierarchical (i.e. that qh = 1) and in fact
dominated by regulation of gene expression. Others
thought that only regulation at the metabolic (qm) level,
thus through the concentrations of substrate, products and
modifiers, was of importance. Experimental regulation
analysis has examined this for Trypanosoma brucei (ter
Kuile and Westerhoff 2001) and Saccharomyces cerevisiae
(Rossell et al. 2006; Daran-Lapujade et al. 2007) and found
the regulation to be distributed between gene expression
and metabolic regulation and to vary over time (Eunen
et al. 2009). Both earlier groups of scientists were right and
wrong.
qh is measured as the ratio between the percentage
change in enzyme concentration and percentage change
in flux accompanying (and being partly caused by) this
change.
qh ¼
logVmax c1 ÿ logVmax c2
log Jc1 ÿ log Jc2
In words, the difference of the logarithm of the Vmax
between condition 1 and 2 (c1 and c2) is divided by the
difference of the logarithm of the flux flowing through the
enzyme in c1 and c2. If a precisely proportional change in
enzyme level (or Vmax) accompanies the change in flux
through that enzyme, then qh will be one and there will be
no regulation of flux through metabolite level changes. If
this is not the case, then some of the flux is metabolically
regulated (qm). qm is given by the percentage change in the
metabolites’ concentration dependence of the enzyme rate
divided by the change in flux. Because the two coefficients
add up to 1, and qh can be measured relatively readily, qm
is usually calculated from the former.
qm ¼ 1ÿ qh
In the presence of drugs, fluxes such as the synthesis rate
of glutathione may change either because of the direct effect
of the drug or its metabolites or because of subsequent
regulation of the fluxes by the cell, in response to the addition
of the drug. The regulation can consist of a combination of
three components, that is, alteration in the levels of
intermediary metabolites such as ATP or glutamate,
alterations in the expression levels of the participating
enzymes or alterations in covalent modification of the
enzymes. Regulation analysis enables one to dissect the three
effects and to suggest ways to optimise the response.
Metabolic network analysis: elementary mode analysis
(EMA), metabolic flux analysis (MFA) and flux balance
analysis (FBA)
MCA and RA flourish by looking at specific aspects of
dynamic networks only, that is, control and regulation,
respectively. One may also focus on flux itself, in the sense
of what fluxes are admitted by a given network model
(EMA), what fluxes are actually occurring (MFA) and what
fluxes correspond to the network fulfilling certain aims
(FBA). The map of a metabolic network (or a mathematical
model thereof) is completely defined by all the reaction
stoichiometries: every reaction in a biological system has a
stoichiometry, which defines the number of substrate and
product molecules that are consumed and produced,
respectively, per turnover of the enzyme (Westerhoff and
van Dam 1987). The stoichiometric matrix is one where the
rows represent the compounds of the reactions and the
columns correspond to the reactions. For the network given
in Fig. 6, the stoichiometric matrix is (1 -1 -1), indicating
that the change in time of the concentration of metabolite
X is v1–v2–v3.
Elementary mode analysis (EMA) studies the possible
routes through a biochemical network. This requires only
stoichiometric data. A flux mode is a set of fluxes through
reaction steps in the network for which each metabolite is
balanced in the sense that its production rate equals its net
consumption rate. The sum of two flux modes is also a flux
mode, and thereby, some flux modes can be described as
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linear combination of two other flux modes. An elementary
flux mode is a minimum set of reactions that can operate at
steady state (Fig. 6). The mode is termed non-decompos-
able or minimal in the sense that removal of any of the
reactions in the mode (knock out of any of the corre-
sponding genes) destroys the flux (Schuster et al. 1999). It
can also be described as a minimal set of reactions needed
to convert one reactant into one metabolic product or a
small set of the latter (Schilling et al. 2000).
Another term often used in this kind of analysis is
‘extreme pathways’. Extreme pathways are a subset of
elementary modes and are distinguishable in that they can-
not be expressed as the combination of more than one ele-
mentary mode. Elementary mode analysis enumerates all
distinct metabolic routes through a network, that is, all
possible flux pathways in a generalised sense. Extreme
pathways analysis on the other hand focuses on enumerating
the unique and minimal set of convex basis vectors needed
to describe all allowable steady state flux distributions
through the metabolic network as sums (not differences) of
the extreme pathways (Papin et al. 2003). In large biological
networks, many, more than one, elementary modes can be
present. These elementary modes may overlap, using the
same reactions or metabolites, depending on the connec-
tivity of the metabolites. The number of, and reaction stoi-
chiometries within, elementary modes can be calculated
using software such as COPASI (Hoops et al. 2006). For
genome-wide networks, the number can be so large that it
defeats the purpose of calculating all of them. In the
example of Fig. 6, the three elementary modes are (1 1 0),
that is, v1 = v2, = v3 = 0, and (1 0 1), that is, v1 = v3,
and (0 1 -1), that is, v2 = reverse v3. Because the first
pathway can be seen as the sum of the latter two, there are
only two extreme pathways, that is, the latter two elemen-
tary modes.
Elementary modes may be associated with biological
functions: the catabolic network of an organism may need
to produce glutamate for protein synthesis and glutathione
for detoxification. Starting from glucose and ammonia,
there may be only a few elementary modes (fundamental
pathways) doing this. In order to understand life, we need
to improve our knowledge and understanding of the role of
the elementary modes and which, how and why certain
ones or certain combinations are used more than others.
EMA was performed on the glutathione model using the
JaPathways software package for the calculation of elemen-
tary mode flux values (Taylor and Schwartz, manuscript in
preparation), which is based on the quadratic programming
approach suggested bySchwartz andKanehisa (Schwartz and
Kanehisa 2005). Steady state flux values calculated for 3
paracetamol concentrations from Geenen et al. (in press)
were used as input to the JaPathways software along with the
stoichiometric coefficients of the model. This resulted in a
complete set of 86 elementary modes and the corresponding
elementary utilisation (flux going through each elementary
mode). The elementarymode with the highest utilisation was
EM1 (shown in Fig. 7), consistent with our identification of a
dominant flux mode shown above.
Elementary modes are related to function. By comparing
the flux flowing through the elementary mode associated
with methionine being used for glutathione recycling
(EM29) to the flux through the elementary mode associated
with methionine being used for detoxification (EM28), we
could analyse and quantify how the cell deals with different
concentrations of paracetamol (Fig. 8). As paracetamol is
increased, the flux going through glutathione recycling
(EM29) reduces as the cell is using more of its glutathione
to detoxify paracetamol (EM28). By analysing the flux
through an elementary mode rather than the flux through a
single reaction, we are able to compare ‘functions’ of the
model rather than merely reactions.
The ‘what is possible question’ is addressed by EMA.
Although software is in place to calculate the flux through
elementary modes, this software is at early stages of
development and is considered rather specialised (Poolman
Fig. 6 Demonstration of how a network can be decomposed into a
set of elementary modes and extreme pathways Fig. 7 The schematic of EM1 and its usage (flux going through this
elementary mode at steady states of three paracetamol concentrations)
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et al. 2004; Schwartz and Kanehisa 2005; Schwartz and
Kanehisa 2006). The ‘how’ question is related to kinetic
properties of and expression levels of enzymes catalysing
the steps in the elementary modes. This question is not
addressed by EMA, but by kinetics, MCA and HRA. The
‘why’ question may have to do with the performance of the
elementary modes in terms of efficiency. This question is
addressed by FBA.
The ‘which’ questions are addressed by metabolic flux
analysis (MFA). The aim of metabolic flux analysis (MFA)
is to quantify the amount of flux going through the
metabolism of an organism. The end result would be a flux
map that shows the distribution of anabolic and catabolic
fluxes over the metabolic network (Wiechert 2001). This is
the combination of flux data gained from, for example,
13C-labelled substrate with the stoichiometric matrix of the
network. This can use either of the two approaches.
Method 1 integrates the 13C data with computer models of
the network being measured. Calculated fluxes through the
model are iteratively fitted to measured data, thereby
minimising the difference between the observed and
simulated isotope spectra, similar to a parameter-fitting
procedure. Method 2 studies flux ratios and is derived by
probabilistic equations that quantify the relative contribu-
tion of converging pathways to the formation of a metab-
olite from the NMR or mass spectra. However, this method
is only appropriate for smaller data sets (10–15 fluxes)
(Wiechert 2001).
An example of MFA is a study on the carbon cycle of
hepatoma cells to investigate potential drug targets. Using
a combination of metabolite concentration information and
transient 13C-labelling experimental data obtained in hep-
atoma cell lines, a network model of glycolysis, the pen-
tose-phosphate pathway (PPP) and the citric acid cycle
(TCA) was set up. The fluxes from the model were then
estimated and found to be in accordance with in vivo 13C-
labelling data (Hofmann et al. 2008; Maier et al. 2008).
The comprehensive network model of Maier et al. (2008)
was extended and applied to modelling cholesterol and
central carbon metabolism. This found 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMG-CoA reduc-
tase) to be a potent target for lowering cholesterol synthesis
Fig. 8 Scheme of EM29 (elementary mode associated with methionine being used for glutathione recycling) and EM28 (elementary mode
associated with methionine being used for detoxification) and the flux going through each elementary mode at three paracetamol concentrations
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with hypolipidemic drugs. By applying MCA to this model,
they found a high (0.5) control coefficient of HMG–CoA
reductase over cholesterol efflux (Maier et al. 2009).
Another example of successful flux analysis is the
investigation of hepatic metabolic pathways in order to
provide nutritional support and non-surgical medical ther-
apies for fulminant hepatic failure (FHF) (Arai et al. 2001).
Here, a mass balance model was created to characterise
changes in liver metabolism during the hypermetabolic
response to injury. By combining experimental data about
amino acid perturbation during FHF with the mass balance
model, it was possible to estimate intrahepatic metabolic
fluxes under treatment conditions. D-galactosamine treat-
ment, for example, significantly decreased hepatic gluco-
neogenesis, which correlated with a reduction in amino
acid entry into various points of the tricarboxylic acid
(TCA) cycle.
By contrast, flux balance analysis (FBA) does not rely on
the input of experimental data or any expression of kinetic
information. Instead, it simulates the metabolic network by
using the stoichiometric matrix to find the pattern of fluxes
while optimising for certain criteria such as the maximal
production of certain products or the minimisation of ATP
hydrolysis (Stelling et al. 2002; Kauffman et al. 2003). This
linear optimisation will ideally result in a single steady state
reaction flux distribution in a metabolic network (Raman
and Chandra 2009), but in practice it does not do so, as there
are many parallel pathways in most networks with, for
example, equal ATP stoichiometries.
The investigation of the fluxes is very important for a
network understanding of a system. The ability to manip-
ulate the fluxes through the system would give scientists
more control over toxicology pathways. The prediction of
the effects of complete inhibition of certain reactions can
be carried out by FBA, but only when the optimisation
criteria ‘used’ in the evolutionary selection for fitness is
known, which is rarely the case (Simeonidis et al. 2010).
The manipulation of fluxes by partial impediment or by
stimulation of steps in the network will require MCA or
full-out kinetic modelling.
Robustness
Robustness is a system’s ability to respond to changes in
the external conditions or internal organisation while
maintaining a constant behaviour and a similar steady state
(Barabasi and Oltvai 2004). Metabolites in biological
systems are clustered into nodes. Some of these nodes are
hubs that are connected with many other nodes. The
topology of a system has a high importance in robustness.
While deletions of individual nodes of a system affect the
system to a small degree, elimination of hubs causes major
disruption as this leaves small isolated node clusters
uninteracting (Albert et al. 2000). Not only topology but
also gene duplication can play an important part in
robustness (Daniels et al. 2008). To understand network
robustness requires investigation into the functional and
dynamic changes that a perturbation causes (Barabasi and
Oltvai 2004), thereby viewing robustness as the systems
property that it is seen to be (Barkai and Leibler 1997).
Many different mathematical approaches have been
used to compare robustness of systems (Daniels et al. 2008;
Grimbs et al. 2007). Westerhoff showed that the higher the
robustness of a variable towards changes in enzyme
activities, the lower the fragility and the lower the corre-
sponding concentration control coefficient (Westerhoff
2007). He also showed (in preparation) that total fragility
of a concentration is always conserved and equal to 0, but
that total robustness is not conserved and is high when
some fragilities are close to zero and high when all fra-
gilities differ strongly from zero. Robustness can be cal-
culated as being the inverse of the control coefficients
(Koefoed et al. 2002; Swat et al. 2011).
In Geenen et al. (in press), it was shown that the con-
centrations of proposed extracellular biomarkers of intra-
cellular glutathione levels were sensitive to methionine
concentrations in the cell. To investigate this, the robust-
ness coefficients were calculated for the biomarkers’
secretion flux (v32 and v38) when perturbing methionine
import (v39) and methionine entry into the methionine
cycle (v1 and v2). The fragility coefficient was evaluated as
the inverse of the flux control coefficient. The results in
Table 3 show that at zero paracetamol, the robustness is
fairly low, with a slightly higher robustness in 5-oxoproline
secretion. This means that the 5-oxoproline secretion is less
likely to change than the ophthalmic acid efflux when the
flux of v39, v1 and v2 changes, making 5-oxoproline the
more robust biomarker of glutathione levels. The negative
robustness merely means that an increase in the flux
through the perturbed process results in a decrease in the
5-oxoproline or ophthalmic acid flux. Interestingly, at low
paracetamol (20 lM), where Geenen et al. (in press)
showed 5-oxoproline could behave as a biomarker for
glutathione depletion, oxoproline secretion flux is more
robust to changes in v39, v1 and v2 than in the absence of
paracetamol. In contrast, at high methionine concentra-
tions, 5-oxoproline secretion flux again has a lower
robustness again, and ophthalmic acid secretion flux has a
high robustness with regard to v39, v1 and v2. This suggests
that 5-oxoproline might be a better biomarker at low par-
acetamol exposure and ophthalmic acid a better biomarker
at high paracetamol concentrations.
Another way to make quantitative predictions on the
relative importance of various reactions in a network uses
flux balance analysis. Several publications have shown that
the flux distribution in organisms like Escherichia coli is
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not homogeneous (Almaas et al. 2004). Most reactions
have quite small fluxes while a few have high flux. It is
likely that perturbations affecting these high flux reactions
will alter the performance of the system most.
Conclusion: how could systems biology help systems
toxicology?
As mentioned above, we have applied a range of systems
biology tools to the glutathione detoxification pathway to
illustrate how these tools can be used to understand how
toxicologically relevant pathways function. We have shown
how steady state analysis of a system can allow us to
investigate system behaviour. In silico experiments in
which the Vmax of the enzyme glutathione synthetase (GS)
in the glutathione pathway was perturbed have allowed us
to simulate a 5-oxoprolinuria patient and to predict the
subsequent increase in 5-oxoproline production. Metabolic
control analysis (MCA) has enabled us to explore the
impact of individual reactions on control of flux through the
glutathione pathways. In the case of 5-oxoprolinuria, this
analysis showed that a decrease in the Vmax of GS resulted
in an increased impact of this enzyme on glutathione syn-
thesis flux, thereby making GS a more rate-determining
enzyme: this mechanism of 5-oxoprolinuria should become
progressively more severe as the molecular defect is
stronger. By contrast, the mechanism of a defect in 5-ox-
oprolinase should have a limited oxoprolinuria effect,
which should not increase further as the molecular defect
increases in severity. Tools like metabolic control analysis
may well be of more general utility in toxicology, for
example, for determining which enzymes in multistep
detoxification pathways are rate determining and can be
expected to exert the greatest effect when perturbed by
dietary effects or single-nucleotide polymorphisms. This
has been exemplified in the demonstration that the supply
reactions of methionine have high control on paracetamol
detoxification, thereby predicting that reduced amounts of
this amino acid (e.g. following malnutrition) could lead to
problems in detoxification (Geenen et al. in press). We have
also applied tools such as metabolic flux analysis (MFA),
flux balance analysis (FBA) and elementary mode analysis
(EMA) to the glutathione pathway, in order to explore the
mechanisms by which changes in discrete analytes arising
from the pathway correlate with glutathione levels and
therefore provide useful biomarkers. It was shown that
EMA can give us information about the flux through a
function, such as detoxification, rather than just the rate of
the reaction. Robustness is an important systems property to
analyse for toxicology, as it can predict the expected level
of change as the system responds to external conditions
such as a toxic effect. By analysing robustness of the glu-
tathione depletion biomarkers, we could investigate under
what condition these biomarkers were robust and therefore
more likely to exhibit a reliable correlation with glutathione
status. We would recommend that when biomarkers are
proposed, not only their sensitivity towards changes in the
phenomenon they are marking should be discussed, but also
their robustness with respect to various SNPs and nutri-
tional variations. This comes on top of our earlier recom-
mendation that the variation of the biomarker concentration
with the property that the biomarker is supposed to monitor
should be monitonic (Geenen et al. in press).
When applying systems biology tools to toxicology
problems, it pays to define the specific issue that needs to
be addressed. To do this, it is important to take full account
of the context. Within the pharmaceutical industry, toxicity
caused by candidate drugs remains a leading cause of
failure of progressing candidate drugs to the market.
Pharmaceutical R&D comprises of distinct Discovery and
Development activities (Fig. 9). Drug Discovery aims to
predict the efficacy and toxicity in man during compound
design and selection, and then to assess potential toxicity in
man by undertaking preclinical safety studies in experi-
mental animals. The approaches used at this early stage are
focussed on reproducible and dose-dependent adverse
effects, not on infrequent events that may occur only in
relatively few highly susceptible individuals. During drug
Development, studies are undertaken that provide accurate
assessment of efficacy and toxicity exhibited by patients in
clinical trials, which as molecules progress through the
development pipeline typically involve progressively lar-
ger numbers of patients and longer durations of compound
administration. This results in a shift in emphasis from
‘average efficacy and toxicity across the human popula-
tion’ in Discovery and in early clinical trials to ‘individual
response and toxicity in each patient’ in Development, that
is, in later trials and after licensing. Where marked
Table 3 The robustness of ophthalmic acid and 5-oxoproline secre-
tion vis-a`-vis perturbation of methionine import (v39) and methionine
entry into the methionine cycle (v1 and v2)
V39 V1 V2
0 lM paracetamol
Ophthalmic acid efflux -0.43 -0.76 -1.4
5-Oxoproline efflux -1.8 -3.1 -5.7
20 lM paracetamol
Ophthalmic acid efflux -0.69 -1.2 -2.4
5-Oxoproline efflux -13 -24 -46
500 lM paracetamol
Ophthalmic acid efflux -39 -73 -140
5-Oxoproline efflux 0.84 1.6 3
Control coefficients were calculated in COPASI and then inversed to
get fragility coefficients
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variability in efficacy or in toxicity is observed in man, the
opportunity arises for personalised health care in which the
relevant drug may be given only to certain patients who are
considered likely to benefit (e.g. the anticancer drug Iressa
is specific to patients with EGF-stimulated tumour cell
growth (Wakeling et al. 2002; Ciardiello et al. 2000)), or
may not be given to patients who are at high risk of
exhibiting a serious adverse event (e.g. the association
in Han Chinese between a genetic marker, HLA–B*1502,
and carbamazepine-induced Stevens–Johnson syndrome
(Chung et al. 2004)).
In principle, systems modelling has the potential to aid
this process significantly. Modelling of data from non-
clinical sources may improve the accuracy of predictions of
effects that occur in the clinic before the first time in man
(FTIM) clinical trial. Such effects may arise from processes
with significant control that exhibit inter-species variation
between animals and man or inter-individual variation
between humans. Figure 10 provides examples of how
such considerations can impact upon the risk of drug-
induced liver injury (DILI) caused by paracetamol, where
the toxicity is caused by a reactive intermediate, which at
normal therapeutic doses is detoxified by conjugation to
glutathione.
We can investigate the toxic effect of paracetamol in the
liver in several different ways. Using pharmacokinetic
modelling, it is possible to predict the concentration of
paracetamol in the liver following administration of dif-
ferent doses and in different individuals (who vary in age,
size, etc.). By modelling the metabolism of the drug, it is
possible to predict how the steady state flux and concen-
tration changes with different doses. This can increase the
understanding of paracetamol toxicity and also identify
doses at which its administration is safe and does not cause
a depletion in glutathione and consequently protein bind-
ing. Tools like metabolic control analysis allow us to
predict which steps have the highest control on important
concentrations and fluxes in the intracellular network. They
can therefore be applied to toxicology to find the steps in
pathways that are more sensitive to toxic effects.
By using systems biology tools such as control and
robustness analysis vis-a`-vis toxicology pathways, one
should be able to provide better understanding and pre-
diction of toxicological risk. The available tools can assess
which parts of a toxicology pathway are most fragile and to
which variations the fragilities are high. This includes the
variability caused by single-nucleotide polymorphisms in
individuals putting them at risk of a, then predictable, toxic
effect. Once such an analysis has been undertaken, part of
the subsequent biomonitoring activities could focus on the
genetic basis of the most controlling steps rather than
requiring the analysis of all possible components of the
Fig. 9 The drug development process
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pathway. This could help assess the potential range of
toxicity for the human population, but also open up ave-
nues for personalised medicine. Here, individual genome
sequences and the frequencies of the polymorphisms in the
human population might have impact, at last. A different
set of biomonitoring activities would read the patients at
more physiological levels, ranging from the expressed
proteome, to metabolomics and personal drug tolerance
history. Here, the results would be compared with results of
systems biology models such as the one discussed here for
glutathione.
In the case of paracetamol, it has already been shown
experimentally that the methionine supply to the cell is a
controlling factor for glutathione detoxification ability.
This has been put into mechanistic perspective by model-
ling. Reduced methionine levels are linked to lower glu-
tathione detoxification ability. Since hepatic glutathione
protects against liver toxicity caused by the reactive
metabolites of paracetamol, an understanding of the range
and variability of the hepatic methionine status in the
human population would be expected to improve our
understanding of the range of doses at which paracetamol
is safe in man. For a candidate drug that causes DILI via
mechanisms similar to those described for paracetamol,
this approach could greatly assist with point 2 in the drug
Development phase goals (Fig. 9) and allow us to more
accurately translate from clinical trial data to human pop-
ulation safety predictions. If it is known how an individual
may be different from the average of the population in a
controlling step, we can more accurately calculate indi-
vidual risk and potentially avoid adverse toxic effects. This
would then be addressing point 3 in the drug Development
phase goals and act as a step towards personalised health
care. In principle, a similar systems modelling approach
could be used to explore and understand risk of toxicity
arising via other mechanisms, provided that the key path-
ways responsible for toxicity and for detoxification can be
defined and flux controlling steps can be identified.
One of the main impacts of the glutathione model was
that the increase in our understanding of the robustness of
the biomarkers 5-oxoproline and ophthalmic acid. Bio-
markers like these could play an important role in tracking
toxicity both during clinical trials and in patients. Model-
ling approaches would allow us to predict and understand
the kinetics, magnitude and dynamic range of these bio-
markers. Therefore, these techniques could allow us to
optimise biomarker usage and help make decisions with
regards to prioritisation between candidates. This would
greatly assist with point 1 in the drug Development phase
goals of Fig. 9 and possibly enable improved monitoring of
drug safety in man in clinical trials.
We have shown that systems biology tools give more
rigorous descriptions of complex biological processes and
effects of perturbations. This has led and will lead to a
better understanding of controlling events and regulatory
processes in the system. Toxicology is a consequence of
the loss of homeostatic regulatory processes, that is, of a
loss of robustness (for example, in the case of toxicity due
to paracetamol, cell protection is overwhelmed by high
doses of reactive metabolites). Therefore, as illustrated
here, the application of systems biology tools to toxicology
has the unique opportunity to provide network insights into
underlying mechanisms and basis of susceptibility to drug
compounds. We also infer that by integrating data for
individuals, such as enzyme activities or diet into a model,
it may in the future be possible to help understand why
Fig. 10 How can systems
biology tools be applied to the
risk of drug-induced liver injury
(DILI) from paracetamol?
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certain individuals are more susceptible to adverse effect of
drugs than others. It may become possible to adjust drug
dosing accordingly, making drugs more effective for
individuals not subject to their toxicity and safer for those
who are.
In the above sections, we asserted that in principle,
systems biology could be far superior over current toxi-
cology methods: clinical trials in human, in vivo work in
animal models and in vitro drug testing in cell lines. We
here wish to repeat that this superiority is far from being in
place. For models to attain the required level of quality and
detail, much more experimental work is needed. At present,
the model quality is insufficient to claim that the precise
calculations in this review lead to reliable results. In sys-
tems biology, unlike in the genomics revolution 10 years
ago, the necessary work flow towards understanding drug
targeting and toxicity is clear. It is not known with cer-
tainty that this work flow will become successful across the
lines, but it is likely to become so in some cases, such as
glutathione-mediated detoxification of paracetamol. Per-
haps it is time to try.
List of abbreviations
The complete names of the enzymes and metabolites
indicated by acronyms in Fig. 1 are as follows.
Enzyme names and acronyms and EC numbers
Names of metabolites of which the concentrations were
variable (lM)
THF—Tetrahydrofolate
5,10-MTHF—5-10-Methenyltetrahydrofolate
5-MTHF—5-Methyltetrahydrofolate
met—Methionine
SAM—S-adenosylmethionine
SAH—S-adenosylhomocysteine
hcy—Homocysteine
cyt—Cystathionine
ccys—Cytosolic cysteine
bcys—Blood cysteine
glc—c-Glutamyl-cysteine
cGSH—Cytosolic glutathione
bGSH—Blood glutathione
cGSSG—Cytosolic glutathione disulphide
bGSSG—Blood glutathione disulphide
cgly—Cytosolic glycine
cglut—Cytosolic glutamate
Names of metabolites of which the concentrations were
held constant
AB—2-Aminobutyrate (Soga et al. 2006)
bgly—Blood glycine
bglut—Blood glutamate
bmet—Blood methionine (varies in some experiments)
cser—Cytosolic serine
H2O2—Cellular hydrogen peroxide
HCHO—Formaldehyde
OPA—Ophthalmic acid, N-[N-(c-glutamyl)-a-
aminobutyryl]glycine
Oxo—5-Oxoproline, pyroglutamic acid
para—N-acetyl-p-aminophenol/paracetamol/
acetaminophen
Reaction Abbreviations Enzyme name E.C.
number
v[1] mati Methionine adenosyl
transferase I
2.5.1.6
v[2] matiii Methionine adenosyl
transferase III
2.5.1.6
v[3] meth Glycine N-methyltransferase 2.1.1.20
v[4] gnmt DNA methyltransferase 2.1.1.72
v[5] ah S-adenosylhomocysteine
hydrolase
3.3.1.1
v[6] bhmt Betaine-homocysteine
methyltransferase
2.1.1.5
v[7] ms Methionine synthase 2.1.1.13
v[8] cbs Cystathionine gamma-
synthase
4.2.1.22
v[9] ctgl Cystathionase 4.4.1.1
v[10] gcl Glutamylcysteine synthetase 6.3.2.2
v[11] gs Glutathione synthetase 6.3.2.3
v[12] gpx Glutathione peroxidase 1.11.1.9
v[13] gr Glutathione reductase 1.8.1.7
v[24] ggct Gamma-
glutamylcyclotransferase
2.3.2.4
v[25] oxoase 5-oxoprolinase 3.5.2.9
Reaction Abbreviations Enzyme name E.C.
number
v[26] gcs Glutamylcysteine synthetase 6.3.2.2
v[27] gs Glutathione synthetase 6.3.2.3
v[28] ggtp Gamma-
glutamyltranspeptidase
2.3.2.2
v[29] ap Aminopeptidase 3.4.11.2
v[31] ggct Gamma-
glutamylcyclotransferase
2.3.2.4
v[33] gpx Glutathione S-transferase 2.5.1.18
v[34] gpx Glutathione S-transferase 2.5.1.18
v[35] ggtp Gamma-
glutamyltranspeptidase
2.3.2.2
v[36] ccat Cysteine-S-conjugate
N-acetyltransferase
2.3.1.80
Arch Toxicol (2012) 86:1251–1271 1267
123
Acknowledgments HVW is greatly indebted to numerous col-
leagues who have contributed through the years to the developments
of thoughts contained in this paper. HVW would like to thank the
various organisations who contributed to the persistent developments
of the thoughts underlying this review as well to the experimental
testing of those thoughts by funding the corresponding research
programs or their preparations, that is, AstraZeneca, the BBSRC,
EPSRC, NWO-ALW, NWO-CW and NWO-CS, EU-FP7, ESF, and
FEBS. In particular, grants BB/C008219/1, BB/I017186/1, BB/
I004688/1 and EP/D508053/1 are acknowledged. PNT thanks Jean-
Marc Schwartz for discussion.
Conflict of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Appendix: Further details on kinetic modelling
Kinetic equations
This appendix contains additional information on the
equations that are typically used in kinetic modelling.
For a reaction where nA ? mB gives pC ? qD, the mass
action kinetics rate equation is:
v ¼ vþ ÿ vÿ ¼ kþ  ½A
n  ½Bm ÿ kÿ  ½C
p  ½Dq ð1Þ
The properties between the square brackets refer to the
chemical activity or concentration of the compounds in
question. Mass action kinetics describes the time depen-
dence of chemical reaction systems where the molecule
numbers are much higher than 100 (Onsager 1931; West-
erhoff and van Dam 1987) and all participating molecules
are explicit in the reaction equation.
Whether a reaction in a network needs to be modelled as
reversible or not depends on the thermodynamics, that is,
on the free energies. Eq. 1 can be rewritten as (Westerhoff
and van Dam 1987):
v ¼ vþ ÿ vÿ ¼ kþ  ½A
n  ½Bm  ð1ÿ
Keq
C
Þ ð2Þ
where the mass action ratio is defined by:
C ¼
½An  ½Bm
½Cp  ½Dq
ð3Þ
and the equilibrium constant equals the mass action ratio at
equilibrium. The thermodynamics is given by:
ÿDG ¼ R  T  ln
C
Keq
 
¼ ÿDG00 þ RT lnC ð4Þ
DG0
0 is the standard Gibbs free energy difference of the
reaction. This represents the influence of the chemistry on
the direction into which the reactions wants to run.
Whenever this Gibbs free energy difference of reaction is
very negative, the reaction is effectively irreversible, and
Eq. 2 reduces to its irreversible version:
v ¼ vþ ¼ kþ  ½A
n  ½Bm ð5Þ
In the mass action kinetics of the simplest possible
reaction, that is, the ‘irreversible’ unimolecular degradation
of S, the rate (v) of a reaction is therefore dependent on the
reaction rate constant (k) and the substrate concentration
[S] (Hofmeyr 1995).
v ¼ k S½  ð6Þ
Several additional assumptions have to hold for Eq. 6 to
represent the rate of the corresponding enzyme catalysed
irreversible reaction. These assumptions include either that
the reaction is diffusion limited or that the substrate
concentration is low enough for the enzyme not to be
saturated by its substrate (Westerhoff and van Dam 1987;
Cornish-Bowden 1995). In cases where the reaction, which
is being modelled, is reversible, the same assumption
continues to apply, but the backward reaction has to be
included in the rate equation, e.g.:
v ¼ ks S½  ÿ kp P½  ð7Þ
When the reaction is not limited by diffusion, that is, by the
collision of the substrate with the enzyme molecule, a more
representative form of the rate equation for the enzyme
catalysed breakdown of S in the absence of any product
takes into account the maximum rate of the enzyme (Vmax).
This rate of reaction tails off as the substrate concentration
exceeds the KM of the enzyme.
v ¼
Vmax  ½S
KM þ ½S
ð8Þ
This rate equation was derived by Michaelis and Menten
(1913) assuming the opposite of diffusion limitation, that
is, that the binding of substrate S to the enzymes is fast
enough almost to reach equilibrium. Haldane (1930)
relaxed this to the assumption that the enzyme-substrate
concentration reaches steady state. Whenever [S] refers to
the free concentration of the substrate, this equation is valid
at steady state, even if the total enzyme concentration is
high compared with the total substrate concentration. When
the total enzyme concentration is small as compared with
the total substrate concentrations, [S] in the above can be
replaced by the total concentration of the substrate in the
system, which much simplifies the further integration of the
system. In cases where this does not apply, a more accurate
zero derivative potential method may be applied (Ha¨rdin
et al. 2009).
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The reversible form of the Michaelis–Menten equation
is (Westerhoff and van Dam 1987; Cornish-Bowden 1995;
Haldane 1931):
v ¼
Vmaxþ 
½S
KMS
ÿ Vmaxþ 
½P
KMP
1þ ½S
KMS
þ ½P
KMP
¼
Vmaxþ 
½S
KMS
 1ÿ
Keq
C
 
1þ ½S
KMS
þ ½P
KMP
ð9Þ
When reactions are far enough from equilibrium, that is,
‘irreversible’, this reduces to:
v ¼
Vmaxþ 
½S
KMS
1þ ½S
KMS
þ ½P
KMP
ð10Þ
This equation is almost equal to the commonly used
equation Eq. 8, but carries the product inhibition effect
with it. This shows that independent of whether a reaction
is irreversible or not, a modeller should always reckon with
the likelihood that the product inhibits the forward reaction
rate, simply because it necessarily binds to the same site
of the enzyme as the substrate does and competes with
the latter. It is good practice to have product-inhibited
reactions in a model by default. Absence of the product
inhibition terms imposes strong limitations to what controls
the system. The distinction between reversibility and
product inhibition is important.
There are several random order and ordered order
binding equations commonly used in biology, which take
the form of Michaelis–Menten equations but contain more
substrates and products or can model reversible reactions
(Cornish-Bowden 1995).
For many reactions, the rate of reaction is not only
influenced by substrates, products, enzyme concentration
and turnover, but also be allosteric effectors that can
change the rate of turnover of the enzyme. It is often seen
that the function of these allosteric interactions is not only
to couple demand and supply but also to maintain a high
independence between fluxes in competing pathways
(Curien et al. 2009). When the activator binds to a site that
does not affect binding of substrate, the rate equation
changes by adding a prefactor (Cornish-Bowden 1995;
Liebermeister and Klipp 2006). For an activator, this term
depends on the concentration of the activator (A) and the
activation constant (KA) and takes the form:
Activation prefactor ¼
½A
KA þ ½A
ð11Þ
For an inhibitor, this term is dependent on the
concentration of the inhibitor (I) and the inhibition
constant (KI) and would take the form:
Inhibition prefactor ¼
KI
KI þ ½I
ð12Þ
Modelling a dynamic system requires rate equations and
balance equations. There is a balance equation for each
metabolite. For a metabolite S, this reads:
dS
dt
¼ vproduction of S ÿ vconsumption of S; ð13Þ
that is, the increase in the concentration of metabolite S is
equal to the rate of its production minus the rate of its
destruction. In this equation, the reaction stoichiometries
play a role, that is, if a certain reaction produces two
molecules of S rather than 1 per turnover, then its term in
the balance equation has to be multiplied by 2.
Kinetic parameters necessary for this modelling (KI, KA,
Vmax, KMs, KMp, etc.) have been measured in quite a few
enzyme studies. They can be obtained from the literature or
by searching in databases such as BRENDA (http://www.
brenda-enzymes.org/) and by implementing other text
mining tools. Alternatively, they can be measured by well-
known biochemical techniques. Rates of reactions can also
be fitted directly from experimental data. However, this will
not be discussed in detail here.
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